

Polypharmazie in der Behandlung depressiver Störungen

Max Schmauß, Augsburg, und Thomas Messer, Pfaffenhofen

Psychopharmakotherapie 2014;21:237–50.

Literatur

- Adli M, Hollinde DL, Stamm T, et al. Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta-50T/C single nucleotide polymorphism. *Biol Psychiatry* 2007;62:1295–302.
- Adson DE, Kushner MG, Eiben KM, et al. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. *Depress Anxiety* 2004;19:121–6.
- Agid O, Lerer B. Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. *Int J Neuropsychopharmacol* 2003;6:41–9.
- Alpert JE, Papakostas G, Mischoulon D, et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. *J Clin Psychopharmacol* 2004;24:661–4.
- Amsterdam JD, Berwisch N. Treatment of refractory depression with combination reserpine and tricyclic antidepressant therapy. *J Clin Psychopharmacol* 1987;7:238–42.
- Aronson R, Offman HJ, Joffe RT, et al. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. *Arch Gen Psychiatry* 1996;53:842–8.
- Arroll B, Mac Gillivray S, Ogston S, et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. *Ann Fam Med* 2005;3:449–56.
- Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT_{1A} antagonists. *Trends Neurosci* 1996;19:378–83.
- Ballenger JC. The clinical use of carbamazepine in affective disorders. *J Clin Psychiatry [Suppl]* 1988;49:13–9.
- Barbee JG, Jamhour NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. *J Clin Psychiatry* 2002;63 (Suppl 8):737–41.
- Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. *J Clin Psychiatry* 2004;65:975–81.
- Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. *J Clin Psychiatry* 2003;64:403–7.
- Baron BM, Ogden A, Seigel BW, et al. Rapid down regulation of β -adrenoreceptors by co-administration of desipramine and fluoxetine. *Eur J Pharmacol* 1988;154:125–34.
- Bauer M, Linden M. Die Kombination verschiedener Antidepressiva in der Behandlung therapieresistenter Depressionen. *Nervenarzt* 1993;64:343–7.
- Bauer M, Hellweg R, Gräf KJ, Baumgartner A. Treatment of refractory depression with high-dose thyroxine. *Neuropsychopharmacology* 1998;18:444–5.
- Bauer M, Döpfner S. Lithium augmentation in treatment-resistant depression – a meta-analysis of placebo-controlled studies. *J Clin Psychopharmacol* 1999;19:427–34.
- Bauer M, Bschor T, Kunz D, et al. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. *Am J Psychiatry* 2000;157:1429–35.
- Bauer M, Whybrow PC. Thyroid hormone, neural tissue and mood modulation. *World J Biol Psychiatry* 2001;2:57–67.
- Bauer M, Forsthoef A, Baethge C, et al. Lithium augmentation therapy in refractory depression – update 2002. *Eur Arch Psychiatry Clin Neurosci* 2003;253:132–9.
- Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: Results of a randomized, placebo-controlled, double-blind study. *J Clin Psychiatry* 2009;70:540–9.
- Bauer M, Adli M, Bschor T, et al. Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. *Neuropsychobiology* 2010;62:36–42.
- Bauer M, Adli M, Ricken R, et al. Role of lithium augmentation in the management of major depressive disorder. *CNS Drugs* 2014;28:331–42.
- Baumann P, Nil R, Souche A, Montaldi S, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. *J Clin Psychopharmacol* 1996;16:307–14.
- Baumgartner A. Schilddrüsenhormone und depressive Erkrankungen. Teil I. *Nervenarzt* 1993;64:1–10.
- Beasley CM jr., Masica DN, Heiligenstein JH, et al. Possible monoamine oxidase inhibitor serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings. *J Clin Psychopharmacol* 1993;13:312–20.
- Beaumont G. Drug interactions with clomipramine (Anafranil). *J Int Med Res* 1973;1:480–4.
- Bech P, Fava M, Trivedi MH, et al. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. *Acta Psychiatr Scand* 2012;125:342–8.
- Berlanga C, Ortega-Soto HA. A 3-year follow-up of a group of treatment resistant depressed patients with a MAO/tricyclic combination. *J Affect Disord* 1995;34:197–198.
- Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder:

Prof. Dr. Max Schmauß, Bezirkskrankenhaus Augsburg, Dr.-Mack-Straße 1, 86156 Augsburg, E-Mail: m.schmauss@bkh-augsburg.de
Priv.-Doz. Dr. Thomas Messer, Danuvius Klinik GmbH, Krankenhausstraße 8, 85276 Pfaffenhofen

- a multicenter, randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 2007;68:843–53.
30. Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. *CNS spectr* 2009;14:937–48.
 31. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. *J Clin Psychopharmacol* 1995;15:217–22.
 32. Blier P. Medication combination and augmentation strategies in the treatment of major depression. In: Stein DJ, Kupfer DJ, Schatzberg AF (eds.). *The American Psychiatric Publishing Textbook of Mood Disorders*. Washington, DC: American Psychiatric Publishing, 2006: 509–24.
 33. Blier P, Gobbi G, Turcotte JE, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination. *Eur Neuropsychopharmacol* 2009;19:457–65.
 34. Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications form treatment initiation for major depressive disorder: a double-blind randomized study. *Am J Psychiatry* 2010;167:281–8.
 35. Bobo WV, Chen H, Trivedi MH, et al. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report. *J Affect Disord* 2011;133:467–76.
 36. Bodkin JA, Lasser RA, Wines JD, et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. *J Clin Psychiatry* 1997;58:137–45.
 37. Bonnet U. Moclobemide: therapeutic use and clinical studies. *CNS Drug Rev* 2003;9:97–140.
 38. Boukoms A, Mangini L. Pergolide: an antidepressant adjuvant for mood disorders? *Psychopharmacol Bull* 1993;29:207–11.
 39. Boyer EW, Shannon M. The serotonin syndrome. *N Engl J Med* 2005;352:1112–20.
 40. Boyer WF, Feighner JP. The combined use of fluoxetine and bupropion (abstract). 146th Annual Meeting of the American Psychiatric Association, San Francisco 1993.
 41. Bressa GM. S-adenosyl-L-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. *Acta Neurol Scand Suppl* 1994;154:7–14.
 42. Bschor T, Canata B, Müller-Oerlinghausen B, et al. Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. *J Affect Disorders* 2001;64:261–5.
 43. Bschor T, Berghöfer A, Ströhle A, et al. How long should the lithium augmentation strategy be maintained A 1-year-follow-up of a placebo-controlled study in unipolar refractory major depression. *J Clin Psychopharmacol* 2002;22:427–30.
 44. Bschor T, Lewitzka U, Sasse J, et al. Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms. *Pharmacopsychiatry* 2003;36(Suppl 3):230–4.
 45. Bschor T, Lewitzka U, Pfennig A, et al. Fünf- undzwanzig Jahre Lithiumaugmentation. *Nervenarzt* 2007;78:1237–47.
 46. Caglieri-Cingolani R, Bencini A. Due case mortali di reazione tossica per associazione di farmaci antidepressivi inibitori delle monoamino-ossidase e tricyclici. *Riv Pat Nerv Ment* 1982;103:21–31.
 47. Calabrese JR, Suppes T, Sachs GS. A double blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. *J Clin Psychiatry* 1999;60:79–88.
 48. Canadian Psychiatric Association. Clinical guidelines for the treatment of depressive disorders. *Can J Psychiatry* 2001;46(Suppl 1):5–90.
 49. Carpenter LL, Jovic Z, Hall JM, et al. Mirtazapine augmentation in the treatment of refractory depression. *J Clin Psychiatry* 1999;60:45–9.
 50. Carpenter LL, Yasmin S, Price H. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. *Biol Psychiatry* 2002;51:183–8.
 51. Cassano P, Lattanzi L, Fava M, et al. Ropinirole in treatment-resistant depression: a 16-week pilot study. *Can J Psychiatry* 2005;50:357–60.
 52. Charney DS, Price LH, Heninger GR. Desipramine-Yohimbine combination treatment for refractory depression. *Arch Gen Psychiatry* 1986;43:1155–61.
 53. Chiarello RJ, Cole JO. The use of psychostimulants in general psychiatry. *Arch Gen Psychiatry* 1987;44:286–95.
 54. Clayton AH, McGarvey EL, Abouesh AI, et al. Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. *J Clin Psychiatry* 2001;62:185–90.
 55. Cohen SN, Armstrong MF. *Drug interactions: a handbook for clinical use*. Baltimore: Williams & Wilkins, 1974.
 56. Connolly KR, Thase ME. If a first you don't succeed. *Drugs* 2011;7:43–6.
 57. Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. *Depression and Anxiety* 2006;23:364–72.
 58. Coryell W. Augmentation strategies for inadequate antidepressant response: a review of placebo-controlled studies. *Ann Clin Psychiatry* 2000;12:141–6.
 59. Coryell W. The search for improved antidepressant strategies: is bigger better? *Am J Psychiatry* 2011;168:664–6.
 60. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analysis of randomized, placebo-controlled trials. *J Clin Psychiatry* 2007;68:935–40.
 61. Cusin C, Iovieno N, Iosifescu DV, et al. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. *J Clin Psychiatry* 2013;74:636–41.
 62. Dam J, Ryde L, Svejsjo J, et al. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. *Pharmacopsychiatry* 1998;31:48–54.
 63. Dams R, Benijts TH, Lambert WE, et al. A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication. *J Anal Toxicol* 2001;25:147–51.
 64. Davidson J. Adding a tricyclic antidepressant to a monoamine oxidase inhibitor. *J Clin Psychopharmacol* 1982;3:216.
 65. Davidson J, McLeod MN, Law-Yone B, Linnola M. A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. *Arch Gen Psychiatry* 1978;35:639–42.
 66. Davis LL, Kabel D, Patel D, et al. Valproate as an antidepressant in major depressive disorder. *Psychopharmacol Bull* 1996;32:647–52.
 67. Dawson LA, Nguyen HQ. The role of 5-HT_{1A} and 5-HT_{1B/1D} receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-) pindolol. *Neuropharmacology* 2000;39:1044–52.
 68. DeBattista C. Augmentation and combination strategies for depression. *J Psychopharmacol* 2006;20:11–8.
 69. DeBattista C, Doghramji K, Menza M, et al. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. *J Clin Psychiatry* 2003;64:1057–64.
 70. DeBattista C, Solvason HB, Poirier J, et al. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. *J Clin Psychopharmacol* 2003;23:27–30.
 71. Debonnel G, Gobbi G, Turcotte J, et al. The alpha-2 antagonist mirtazapine combined with the SSRI paroxetine induces a greater antidepressant response: a double-blind controlled study. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology, Dec 10–14, San Juan, Puerto Rico 2000.
 72. De la Gandara J, Rojo AL, Ros S, et al. Use of antidepressant combinations: which, when and why? Results of a panish survey. *Acta Psychiatr Scand* 2005;112(Suppl 428):32–6.
 73. De Montigny C. Lithium addition in treatment resistant depression. *Int Clin Psychopharmacol* 1994;9(Suppl 2):31–5.
 74. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN). S3-Leitlinie unipolare Depression. Darmstadt: Steinkopff, 2009.
 75. Devarajan S, Dursun SM. Citalopram plus reboxetine in treatment-resistant depression. *Can J Psychiatry* 2000;45:489–90.
 76. Devarajan S, Dursun SM. Olanzapine plus venlafaxine in treatment-resistant depression. *J Psychopharmacol* 2005;19:434–5.
 77. Dietrich DE, Emrich HM. The use of anticonvulsants to augment antidepressant medication. *J Clin Psychiatry* 1998;59(Suppl 5):51–8.

78. Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. *J Clin Psychopharmacol* 1998;18:465–9.
79. Dodd S, Horgan D, Malhi G, et al. To combine or not to combine? A literature review of antidepressant combination therapy. *J Affect Disord* 2005;89:1–11.
80. Doree JP, Des Rosiers J, Gendron LV, et al. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. *Curr Med Res Opin* 2007;23:333–41.
81. Dunner LD, Amsterdam JD, Shelton RC, et al. Adjunctive ziprasidone in treatment-resistant depression: a pilot study. 156th Annual Meeting of the APA, May 17–22 2003, San Francisco, California USA 2003.
82. Ebert D, Albert R, May A, et al. Combined SSRI-RIMA treatment in refractory depression. Safety data and efficacy. *Psychopharmacology (Berl)* 1995;119:342–4.
83. Edwards SJ, Hamilton V, Nherera L, Trevor N. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation. *Health Technol Assess* 2013;54:1–190.
84. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. *Int J Neuropsychopharmacol* 2010;13:917–32.
85. Erbe S, Gutwinski S, Bschor T. Augmentati-on von Antidepressiva mit atypischen Antipsychotika bei Nonresponse auf eine Antidepressiva-Monotherapie. *Psychiatr Prax* 2012;39:57–63.
86. Erbe S, Pellert UN. Folate in der Depressionsbehandlung. *Fortschr Neurol Psychiatr* 2014;82:78–83.
87. Erfurth A, Möller HJ. Vorgehen bei Antidepressiva-Nonrespondern. In: Möller HJ (Hrsg.). *Therapie psychiatrischer Erkrankungen*. 2. Auflage. Stuttgart, New York: Thieme, 2000: 407–12.
88. Farah A. Relief of SSRI-induced sexual dysfunction with mirtazapine treatment (letter). *J Clin Psychiatry* 1999;60:260–1.
89. Fava M. Augmentation and combination strategies in treatment-resistant depression. *J Clin Psychiatry* 2001;62(Suppl 18):4–11.
90. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. *Psychother Psychosom* 2006;3:139–53.
91. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. *Psychiatr Clin North Am* 1996;19:179–200.
92. Fava M, Rosenbaum JF, Mc Grath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double blind controlled study. *Am J Psychiatry* 1994;151:1372–4.
93. Fava M, Alpert J, Nierenberg AA, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and non-responders to fluoxetine. *J Clin Psychopharmacol* 2002;22:379–87.
94. Fawcett J, Kravietz HM, Zajecka MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. *J Clin Psychopharmacol* 1991;11:127–32.
95. Feighner JP, Herbstein J, Damlouji N. Combination MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. *J Clin Psychiatry* 1985;46:206–9.
96. Feighner JP, Boyer WF, Tyler DL, Neborsky RJ. Adverse consequences of fluoxetine-MAOI combination therapy. *J Clin Psychiatry* 1990;51:222–5.
97. Ferreri M, Lavergne F, Berlin I, et al. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. *Acta Psychiatr Scand* 2001;103:66–72.
98. Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. *Clin Pharmacokinet* 2000;39:413–27.
99. Flockhart DA. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update. *J Clin Psychiatry* 2012;73(Suppl 1):17–24.
100. Fredman SJ, Fava M, Kienke AS, et al. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current “next-step” practices. *J Clin Psychiatry* 2000;61:403–8.
101. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. *J Clin Psychiatry* 2000;61:9–15.
102. Gander DR. Treatment of depressive illnesses with combined antidepressants. *Lancet* 1965;1:107–9.
103. Gerner RH, Kaufman KR, Rosen R. Seizures associated with bupropion and SSRI cotherapy (abstract). *Biol Psychiatry* 1998;43:995.
104. Goforth HW, Carroll BT. Aripiprazole augmentation of tricyclic antidepressants in treatment-resistant major depression. *J Clin Psychopharmacol* 2007;27:216–7.
105. Goldberg RS, Thornton WE. Combined tricyclic-MAOI therapy for refractory depression: a review, with guidelines for appropriate usage. *J Clin Pharmacol* 1978;18:143–7.
106. Goodwin FK, Prange AJ, Post RM, et al. A potentiation of antidepressant effect by l-triiodothyronine in tricyclic nonresponders. *Am J Psychiatry* 1982;139:34–8.
107. Goss AJ, Kaser M, Costafreda SG, et al. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. *J Clin Psychiatry* 2013;74:1101–7.
108. Gupta S, Ghaly N, Dewan M. Augmenting fluoxetine with dextroamphetamine to treat refractory depression. *Hosp Com Psychiatr* 1992;43:281–3.
109. Guscott R, Grof P. The clinical meaning of refractory depression: a review for the clinician. *Am J Psychiatry* 1991;148:695–704.
110. Härter M, Sitta P, Keller F, et al. Stationäre psychiatrisch-psychotherapeutische Depressionsbehandlung. Prozess- und Ergebnisqualität anhand eines Modellprojekts in Baden-Württemberg. *Nervenarzt* 2004;75:1083–91.
111. Harkin A, Kelly JP, McNamara M, et al. Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. *Eur J Pharmacol* 1999;364:123–32.
112. Hawley C, Sivakumaran T, Ochocki M, Bevan J. Coadministration therapy with reboxetine and serotonin specific reuptake inhibitors in twenty-four patients with major depression (abstract). 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP) Brussels 2000.
113. Hawley CJ, Loughlin PJ, Quick SJ, et al. Efficacy, safety and tolerability of combined administration of lithium and selective serotonin reuptake inhibitors: a review of the current evidence. *Int Clin Psychopharmacology* 2000;15:197–206.
114. Hawley CJ, Quick SJ, Ratnam S. Safety and tolerability of combined treatment with moclobemide and SSRI: a systematic study of 50 patients. *Int Clin Psychopharmacol* 1996;11:187–91.
115. Hodgman MJ, Martin TG, Krenzelok EP. Serotonin syndrome due to venlafaxine and maintenance tricyclic antidepressant therapy. *Human Exp Toxicol* 1997;16:14–7.
116. Hüttemann K, Nowe T, Köhrmann M, et al. Maligne Hyperthermie und deren Differentialdiagnosen. *Fortschr Neurol Psychiatr* 2009;77:203–11.
117. Inoue T, Tsuchiya K, Miura J, et al. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. *Biol Psychiatry* 1996;40:151–3.
118. Iosifescu DV, Nierenberg AA, Mischoulon D, et al. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. *J Clin Psychiatry* 2005;66:1038–42.
119. Joffe RT, Roy-Byrne PP, Uhde TW, Post RM. Thyroid function and affective illness: a reappraisal. *Biol Psychiatry* 1984;19:1685–91.
120. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. *Arch Gen Psychiatry* 1993;50:387–93.
121. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. *J Clin Psychiatry* 1993;54:269–71.
122. Joffe RT, Lewitt AJ, Bagby RM, et al. Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic nonresponders. *Br J Psychiatry* 1993;163:574–8.

123. Joffe RT, Bakish D. Combined SSRI-moclobemide treatment of psychiatric illness. *J Clin Psychiatry* 1994;55:24–5.
124. Joffe RT, Sokolov ST. Thyroid hormones, the brain, and affective disorders. *Crit Rev Neurobiol* 1994;8:45–63.
125. Johnson GF. Lithium in depression: a review of the antidepressant and prophylactic effects of lithium. *Aust NZJ Psychiatry* 1987;21:356–65.
126. Keitner GI, Garlow SJ, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. *J Psychiatr Res* 2009;43:205–14.
127. Keltner N, Harris CP. Serotonin syndrome: a case of fatal SSRI/MAOI interaction. *Perspect Psychiatr Care* 1994;30:26–31.
128. Kemp LI. Sodium valproate as an antidepressant. *Br J Psychiatry* 1992;160:121–3.
129. Köhler S, Stöver L, Bschor T. MAO-Hemmer als Behandlungsoption der therapieresistenten Depression: Anwendung, Wirksamkeit und Besonderheiten. *Fortschr Neurol Psychiatr* 2014;82:228–38.
130. Köhler S, Unger T, Hoffmann S. Comparing augmentation with non-antidepressants over sticking to antidepressants after treatment failure in depression: a naturalistic study. *Pharmacopsychiatry* 2013;46:69–76.
131. Koenig F, Baumann P, Wolfersdorf M, et al. Hypertensive Reaktion nach Kombinations-therapie von Moclobemid, Trimipramin und Omeprazol. *Nervenheilkunde* 1997;16:55–9.
132. Koenig F, Wolfersdorf M. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression. *Pharmacopsychiatry* 1997;30:93–6.
133. Konstantinidis A, Papageorgiou K, Grohmann R, et al. Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. *Int J Neuropsychopharmacol* 2012;15:449–57.
134. Labbate LA, Grimes JB, Hines A, et al. Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction. *Ann Clin Psychiatry* 1997;9:241–5.
135. Lam RW, Wan DD, Cohen NL, Kennedy SH. Combining antidepressants for treatment-resistant depression. A review. *J Clin Psychiatry* 2002;63:685–93.
136. Lam RW, Hossie H, Solomons K, et al. Citalopram and bupropion SR: combining vs. switching in patients with treatment-resistant depression. *J Clin Psychiatry* 2004;65:337–40.
137. Landen M, Bjorling G, Agren H, et al. A randomized, double-blind, placebocontrolled trial of buspirone in combination with an SSRI in patients with treatment refractory depression. *J Clin Psychiatry* 1998;59:664–8.
138. Lattanzi L, Cassano P, Dell’Osso L, et al. Adjunctive pramipexole in treatment resistant depression. Presented at the 39th annual meeting of the American College of Neuro-psychopharmacology Dec 10–14 San Juan, Puerto Rico 2000.
139. Lejoyeux M, Adès J, Rouillon F. Serotonin syndrome. Incidence, symptoms and treatment. *CNS Drugs* 1994;2:132–43.
140. Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment: a randomised study of extended duration of treatment, dose increase or mianserin augmentation. *Psychopharmacology (Berl)* 2002;161:143–51.
141. Linet LS. Treatment of a refractory depression with a combination of fluoxetine and d-amphetamine (letter). *Am J Psychiatry* 1989;146:803–4.
142. Loveless AH, Maxwell DR. A comparison of the effects of imipramine, trimipramine, and some other drugs in rabbits treated with a monoamine oxidase inhibitor. *Br J Pharmacol* 1965;25:158–70.
143. Lucca A, Serretti A, Smeraldi E. Effect of reboxetine augmentation in SSRI resistant patients. *Hum Psychopharmacol* 2000;15:143–5.
144. Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. *J Affect Disord* 1996;41:201–10.
145. Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder. A randomized trial. *Ann Intern Med* 2007;147:593–602.
146. Marangell LB, Johnson CR, Kertz B, et al. Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study. *J Clin Psychiatry* 2002;63:391–5.
147. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder. *J Clin Psychopharmacol* 2008;28:156–65.
148. Marks J. Interaction involving drugs used in psychiatry. In: Marks J, Pare CMB (eds.). *The scientific basis of drug therapy in psychiatry*. Oxford: Pergamon, 1965:191–201.
149. Marley E, Wozniak KM. Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine reuptake inhibitors. *Psychol Med* 1983;13:735–49.
150. Marshall RD, Randall D, Johannet CM, et al. Bupropion and sertraline combination treatment in refractory depression. *J Psychopharmacol* 1995;9:284–6.
151. Marshall RD, Liebowitz MR. Paroxetine/bupropion combination treatment for refractory depression. *J Clin Psychopharmacol* 1996;16:80–1.
152. Mc Clellan KJ, Spencer CM. Modafinil – a review of its pharmacology and clinical efficacy in the management of narcolepsy. *CNS Drugs* 1998;9:311–24.
153. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a Star*D report. *Am J Psychiatry* 2006;163:1531–41.
154. McIntyre RS, Muller A, Mancini DA, et al. What to do if an initial antidepressant fails? *Can Fam Physician* 2003;49:449–57.
155. Michelson D, Bancroft J, Targum S, et al. Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention. *Am J Psychiatry* 2000;157:239–43.
156. Miller KK, Perlis RH, Papakostas GI, et al. Low-dose transdermal testosterone augmentation therapy improves depression severity in women. *CNS Spectr* 2009;14:688–94.
157. Möller HJ. Therapieresistenz auf Antidepressiva. *Nervenarzt* 2004;75:499–517.
158. Möller HJ. Medikamentöse Therapie-strategien bei therapieresistenter unipolarer Depression. *Psychopharmakotherapie* 2004;11:34–41.
159. Möller HJ, Kissling W, Stoll KD, Wendt G. *Psychopharmakotherapie*. Stuttgart: Kohlhammer, 1989.
160. Möller HJ, Seemüller F, Schennach-Wolf R, et al. History, background, concepts and current use of comedication and polypharmacy in psychiatry. *Int J Neuropsychopharmacology* 2014;17:983–96.
161. Moreno FA, Gelenberg AJ, Bachar K, et al. Pindolol augmentation of treatment-resistant depressed patients. *J Clin Psychiatry* 1997;58:437–9.
162. Morris DW, Budhwar N, Husain M, et al. Depression treatment in patients with general medical conditions: results from the COMED trial. *Ann Fam Med* 2012;10:23–33.
163. Murphy DL, Sunderland T, Cohen RM. Monoamine oxidase-inhibiting antidepressants – a clinical update. *Psychiatr Clin North Am* 1984;7:549–62.
164. Nelson JC. Augmentation strategies with serotonin-noradrenergic combinations. *J Clin Psychiatry* 1998;59:65–8.
165. Nelson JC. Treatment of antidepressant non-responders: augmentation or switch? *J Clin Psychiatry* 1998;59(Suppl 15):35–41.
166. Nelson JC. Augmentation strategies in depression. *J Clin Psychiatry* 2000;61(Suppl 2):13–9.
167. Nelson JC. Managing treatment-resistant major depression. *J Clin Psychiatry* 2003;64:5–12.
168. Nelson JC. S-Adenosyl methionine (S-AdoMet) augmentation in major depressive disorder. *Am J Psychiatry* 2010;167:889–91.
169. Nelson JC, Mazure CM, Bowers MJB, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. *Arch Gen Psychiatry* 1991;48:303–7.
170. Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibitor mechanisms for treatment of depression: a double-blind, randomized study. *Biol Psychiatry* 2004;55:296–300.
171. Nelson JC, Pikelov A, Berman RM. Augmentation treatment in major depressive disorder: focus on aripiprazole. *Neuropsychiatric Dis Treatment* 2008;4:937–48.

172. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. *Am J Psychiatry* 2009;166:980–91.
173. Nelson JC, Thase ME, Trivedi MH, et al. Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled post hoc analysis (studies CN138–139 and CN 138–163). *J Clin Psychiatry* 2009;11:344–52.
174. Nelson JC, Mankoski R, Baker RA, et al. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression. a post-hoc, pooled analysis of two large, placebo-controlled studies. *J Affect Disorders* 2010;120:133–40.
175. Nemeroff CB. Augmentation strategies in patients with refractory depression. *Depress Anxiety* 1996;4:169–81.
176. Neuvonen P, Pohjola-Sintonen S, Tacke U, et al. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. *Lancet* 1993;342:1419.
177. Nierenberg AA, Papakostas GI, Petersen T, et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. *J Clin Psychopharmacol* 2003;23:92–5.
178. Nierenberg AA, Fava M, Trivedi MH. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: A STAR*D report. *Am J Psychiatry* 2006;163:1519–30.
179. Nierenberg AA. Switch or augment? Lessons from STAR*D. *Ann Clin Psychiatry* 2010;22(Suppl):4–8.
180. Norman TR, Sartor DM, McIntyre IM. Clinical and experimental studies on the potentiation of antidepressant drugs by thyroid hormones. *Med Sci Res* 1988;16:545–50.
181. O'Brien S, McKeon P, O'Regan M. The efficacy and tolerability of combined antidepressant treatment in different depressive subgroups. *Br J Psychiatry* 1993;163:363–8.
182. Oefele v. K, Grohmann R, Hippus H, Rütther E. Unerwünschte Arzneimittelwirkungen bei der Kombinationsbehandlung mit trizyklischen Antidepressiva und Monoaminoxidase-Hemmern. *Nervenarzt* 1988;59:118–23.
183. Olver JS, Cryan JF, Burrows GD, et al. Pindolol augmentation of antidepressants: a review and rationale. *Aust N Z J Psychiatry* 2000;34:71–9.
184. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. *J Clin Psychiatry* 1999;60:256–9.
185. Pande AC, Calarco MM, Grunhaus LJ. Combined MAOI-TCA treatment in refractory depression. In: Amsterdam JD (ed.). *Advances in neuropsychiatry and psychopharmacology. Vol. 2: refractory depression.* New York: Raven Press, 1991:115–21.
186. Papakostas GI. Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder. *Essent Psychopharmacol* 2005;6:209–20.
187. Papakostas GI. Evidence for S-Adenosyl-L-Methionine (SAM-e) for the treatment of major depressive disorder. *J Clin Psychiatry* 2009;70:18–22.
188. Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. *J Clin Psychiatry* 2009;70:16–25.
189. Papakostas GI. Switching, combination, and augmentation strategies for major depressive disorder. *Ann Clin Psychiatry* 2010;22:9–14.
190. Papakostas GI, Alpert JE, Fava M. SAMe in the treatment of depression: a comprehensive review of the literature. *Curr Psychiatry Rep* 2003;5:460–6.
191. Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant depressive disorder. *J Clin Psychiatry* 2004;65:217–21.
192. Papakostas GI, Petersen TJ, Kinrys G, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. *J Clin Psychiatry* 2005;66:1326–30.
193. Papakostas GI, Worthington JJ, Iosifescu DV, et al. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. *Depress Anxiety* 2006;3:178–81.
194. Papakostas GI, Shelton RC, Smith J, et al. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. *J Clin Psychiatry* 2007;68:826–31.
195. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. *Biol Psychiatry* 2008;63:699–704.
196. Papakostas GI, Shelton RC. Use of atypical antipsychotics for treatment-resistant major depressive disorder. *Curr Psychiatry Reports* 2008;10:481–6.
197. Papakostas GI, Mischoulon D, Shyu I, et al. S-Adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. *Am J Psychiatry* 2010;167:942–8.
198. Papakostas GI, Shelton RC, Zajecka JM. L-Methylfolate as adjunctive therapy for SSR-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. *Am J Psychiatry* 2012;169:1267–74.
199. Papakostas GI, Cassiello CF, Iovieno N. Folate and S-Adenosylmethionine for major depressive disorder. *Can J Psychiatry* 2012;57:406–13.
200. Pare CMB. Toxicity of psychotropic drugs: side effects and toxic effects of antidepressants. *Proc R Soc Med* 1964;57:757–78.
201. Pare CMB. The present status of monoamine oxidase inhibitors. *Br J Psychiatry* 1985;146:576–84.
202. Perez V, Soler J, Puigdemont D, et al. A double-blind, randomized, placebo controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. *Grup de Recerca en Trastorns Afec-tius. Arch Gen Psychiatry* 1999;56:375–9.
203. Perlis RH, Iosifescu DV, Alpert J, et al. Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. *Psychosomatics* 2004;45:224–9.
204. Petty F, Trivedi MH, Fulton M, Rush AJ. Benzodiazepines as antidepressants: does GABA play a role in depression? *Biol Psychiatry* 1995;38:578–91.
205. Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. *Neuropsychopharmacology* 2006;31:2505–13.
206. Razzani J, White K, White J, Simpson G, et al. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. *Arch Gen Psychiatry* 1983;40:657–61.
207. Reeves H, Batra S, May RS, et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. *J Clin Psychiatry* 2008;69:1228–36.
208. Resler G, Lavie R, Campos J, et al. Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B₁₂, and serotonin levels in lymphocytes. *Neuroimmunomodulation* 2008;15:145–52.
209. Rickels K, Amsterdam JD, Clary C, et al. Buspirone in major depression: a controlled study. *J Clin Psychiatry* 1991;52:34–8.
210. Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. *Clin Pharmacokinet* 2003;42:123–37.
211. Rocha FL, Hara C. Lamotrigine augmentation in unipolar depression. *Int Clin Psychopharmacol* 2003;18:97–9.
212. Ros S, Agüera L, de la Gandara J, et al. Potentiation strategies for treatment-resistant depression. *Acta Psychiatr Scand* 2005;112(Suppl 428):14–24.
213. Rosenthal JS, Kaswan MJ, Hemlock C, Winston A. Fluoxetine enhancement of heterocyclic antidepressants. In: Amsterdam JD (ed.). *Advances in neuropsychiatry and psychopharmacology. Vol. 2: refractory depression.* New York: Raven Press, 1991:105–8.
214. Rothschild BS. Fluoxetine-nortriptyline therapy of treatment resistant major depression in a geriatric patient. *J Geriatric Psych Neurol* 1994;7:137–8.
215. Rubio G, San L, Lopez-Munoz F, et al. Reboxetine adjunct for partial or nonresponders to antidepressant treatment. *J Affect Disord* 2004;81:67–72.

216. Rush AJ, Trivedi MH, Stewart JW. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. *Am J Psychiatry* 2011;168:689–701.
217. Sachs G, Collins MA, Altshuler L, et al. Divalproax sodium versus placebo for the treatment of bipolar depression. APA 2002, Syllabus & Proceedings Summary.
218. Schmauß M. Miscellaneous new developments. In: Hippus H, Winokur G (eds.). *Psychopharmacology 1. Part 2: Clinical psychopharmacology*. Amsterdam, Oxford, Princeton: Excerpta Medica, 1983:178–85.
219. Schmauß M. Kombinationstherapie nicht-selektiver Monoamin-Rückaufnahme-Inhibitoren mit MAO-Hemmern. In: Riederer P, Laux G, Pödlinger W (Hrsg.). *Neuro-Psychopharmaka. Band 3: Antidepressiva, Phasenprophylaktika und Stimmungsstabilisierer*. 2. Auflage. Wien, New York: Springer, 2003: 551–7.
220. Schmauß M, Kapfhammer HP, Meyr P, Hoff P. Combined MAO-inhibitor and tri(tetra) cyclic antidepressant treatment in therapy resistant depression. *Prog Neuro Psychopharmacol Biol Psychiatry* 1988;12:523–32.
221. Schmauß M, Laakmann G, Dieterle D. Effects of alpha-receptor blockade in addition to tricyclic antidepressants in therapy resistant depression. *J Clin Psychopharmacol* 1988;8:108–11.
222. Schmauß M, Erfurth A. Kombinationstherapie bei Therapieresistenz auf Antidepressiva. *Fortschr Neurol Psychiat* 1996;64:390–402.
223. Schmauß M, Messer T. Augmentationsstrategien bei Therapieresistenz auf Antidepressiva. *Psychiat Prax* 2007;34:165–74.
224. Schmauß M, Messer T. Kombination von Antidepressiva – eine sinnvolle Behandlungsstrategie bei therapieresistenten Depressionen? *Fortschr Neurol Psychiat* 2009;77:316–25.
225. Schöpf J. Lithiumzugabe zu Thymoleptika als Behandlung therapieresistenter Depressionen. *Nervenarzt* 1989;60:200–5.
226. Schuckit M, Robins E, Feighner J. Tricyclic antidepressants and monoamine oxidase inhibitors. *Arch Gen Psychiatry* 1971;24:509–14.
227. Schüle C, Baghai TC, Eser D, et al. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. *World J Biol Psychiatry* 2007;8:112–22.
228. Seth R, Jennings AL, Bindman J, Phillips J, et al. Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. *Br J Psychiatry* 1992;161:562–5.
229. Sethna ER. A study of refractory cases of depressive illness and their response to combined antidepressant treatment. *Br J Psychiatry* 1974;124:265–72.
230. Shapira B, Oppenheim G, Zoher J, Segal M, et al. Lack of efficacy of estrogen supplementation to imipramine in resistant female depressives. *Biol Psychiatry* 1985;20:576–9.
231. Shelton RC, Tollefson GD, Tohen M, Stahl S, et al. A novel augmentation strategy for treating resistant major depression. *Am J Psychiatry* 2001;158:131–4.
232. Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. *J Clin Psychiatry* 2005;66:1289–97.
233. Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. *Acta Psychiatr Scand* 2008;117:253–9.
234. Sherwin BB. Estrogen and refractory depression. In: Amsteram JD (ed.). *Advances in neuropsychiatry and psychopharmacology*. Vol. 2: refractory depression. New York: Raven Press, 1991:209–18.
235. Sjöqvist F. Psychotropic drugs II: interaction between monoamine oxidase (MAO) inhibitors and other substances. *Proc R Soc Med* 1965; 58:967–78.
236. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. *Eur Neuropsychopharmacol* 1999;9:83–91.
237. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. *J Clin Psychiatry* 2006;67(Suppl 6):16–22.
238. Spier SA. Use of bupropion with SSRIs and venlafaxine. *Depress Anxiety* 1998;7:73–5.
239. Spiker DG, Pugh DD. Combining tricyclic and monoamine oxidase inhibitor antidepressants. *Arch Gen Psychiatry* 1976;33:828–30.
240. Spillmann M, Fava M. S-adenosylmethionine (Ademetionine) in psychiatric disorders: historical perspective and current status. *CNS Drugs* 1996;6:416–25.
241. Sporn J, Ghaemi SN, Sambur MR, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. *Ann Clin Psychiatry* 2000;12:137–40.
242. Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. *CNS Spectr* 2008;13:855–70.
243. Stein D, Avni J. Thyroid hormones in the treatment of affective disorders. *Acta Psychiatr Scand* 1998;77:623–36.
244. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic resistant depression. A controlled trial using lithium in low and normal doses. *Br J Psychiatry* 1993;162:634–40.
245. Sternbach H. Danger of MAOI therapy after fluoxetine withdrawal. *Lancet* 1988;II:850–1.
246. Stoll AL, Pillay SS, Diamond L, et al. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. *J Clin Psychiatry* 1996;57:72–6.
247. Storosum JG, Elferink AJ, van Zwieten BJ, et al. Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. *Eur Neuropsychopharmacol* 2001;11:173–80.
248. Takahashi H, Kamata M, Yoshida K. Augmentation with olanzapine in TCA-refractory depression with melancholic features: a consecutive case series. *Hum Psychopharmacol Clin Exp* 2008;23:217–20.
249. Targum SD, Greenberg RD, Harmon RL, et al. Thyroid hormone and the TRH stimulation test in refractory depression. *J Clin Psychiatry* 1984;45:345–6.
250. Thase ME. Antidepressant combinations: widely used, but far from empirically validated. *Can J Psychiatry* 2011;56:317–23.
251. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. *J Clin Psychiatry* 1997;58(Suppl 13):23–9.
252. Thase ME, Nelson JS, Papakostas GI, et al. Augmentation strategies in the treatment of major depressive disorder. *CNS Spectr* 2007;12:2–17.
253. Thase ME, Trivedi MH, Nelson JC, et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. *J Clin Psychiatry* 2008;10:440–7.
254. Tohen M, Case M, Trivedi MH. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. *J Clin Psychiatry* 2010;71:451–62.
255. Trivedi MH. Treatment-resistant depression: new therapies on the horizon. *Ann Clin Psychiatry* 2003;15:59–70.
256. Trivedi MH, Kleiber BA. Using treatment algorithms for the effective management of treatment-resistant depression. *J Clin Psychiatry* 2001;62(Suppl 6):22–9.
257. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. *N Engl J Med* 2006;12:1243–52.
258. Vaughan DA. Interaction of fluoxetine with tricyclic antidepressants (letter). *Am J Psychiatry* 1988;145:1478.
259. Volz HP, Gleiter CH, Möller HJ. Monoaminooxidasehemmer in der Psychiatrie. *Nervenarzt* 1996;67:339–47.
260. Warneke L. Psychostimulants in psychiatry. *Can J Psychiatry* 1990;35:3–10.
261. Warner MD, Peabody CA, Whiteford HA, Hollister LE. Alprazolam as an antidepressant. *J Clin Psychiatry* 1988;49:148–50.
262. Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. *J Clin Psychiatry* 1989;50:447–9.
263. Weilburg JB, Rosenbaum JF, Biederman J, et al. Tricyclic augmentation of fluoxetine. *Ann Clin Psychiatry* 1991;3:209–13.
264. White K, Pistole TA, Boyd J. Combined monoamine oxidase inhibitor tricyclic antidepressant treatment. A pilot study. *Am J Psychiatry* 1980;137:1422–5.
265. White K, Simpson G. Combined MAOI-tricyclic antidepressant treatment. A reevaluation.

- ation. *J Clin Psychopharmacol* 1981;1:264–82.
266. Whybrow PC, Prange AJ Jr. A hypothesis of thyroid-catecholamine receptor interaction. *Arch Gen Psychiatry* 1981;38:106–13.
267. Winston F. Combined antidepressant therapy. *Br J Psychiatry* 1971;118:301–4.
268. Young JPR, Lader MH, Hughes WC. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. *Br Med J* 1979;2:1315–7.
269. Young SJ. Panic associated with combining fluoxetine and bupropion (letter). *J Clin Psychiatry* 1996;57:177–8.
270. Zajecka JM, Jeffriess H, Fawcett J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. *J Clin Psychiatry* 1995;56:338–43.
271. Zisook S, Rush AJ, Haight BR, et al. Use of bupropion in combination with serotonin reuptake inhibitors. *Biol Psychiatry* 2006;59:203–10.
272. Zullino D, Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. *Pharmacopsychiatry* 2001;34:119–27.